Related Experiment Videos
High-dose rituximab therapy in chronic lymphocytic leukemia
1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Seminars in Oncology
|February 28, 2001
Summary
Higher doses of rituximab show a dose-response relationship in chronic lymphocytic leukemia (CLL) treatment. This chimeric monoclonal antibody is a promising agent for chemoimmunotherapy strategies in CLL patients.
Area of Science:
- Oncology
- Immunology
Background:
- Rituximab is a chimeric monoclonal antibody targeting mature B cells, approved for B-cell lymphoma therapy.
- Initial trials showed <20% activity for rituximab in small lymphocytic lymphoma (CLL counterpart).
- Lower CD20 antigen density and shorter rituximab half-life in CLL limit its efficacy.
Purpose of the Study:
- To increase rituximab activity in chronic lymphocytic leukemia (CLL).
- To overcome challenges of lower CD20 antigen density and shorter rituximab half-life in CLL.
- To evaluate safety and efficacy of escalated rituximab doses in CLL patients.
Main Methods:
- Phase I dose-escalation study.
- Patients received escalated rituximab doses on weeks 2, 3, and 4 after an initial 375 mg/m2 dose.
- Maximum evaluated dose was 2,250 mg/m2.
Main Results:
- A clear dose-response relationship was observed.
- Severe toxicity (grades 3-4) was uncommon in typical CLL, unlike in mantle cell lymphoma and prolymphocytic leukemia.
- No unusual toxicity was noted at higher rituximab doses.
Conclusions:
- Escalated rituximab dosing shows promise for CLL treatment.
- Further research on dosing schedules and combination therapies is warranted.
- Rituximab may be effective in chemoimmunotherapy for front-line and relapsed CLL.